Investors Sell Celgene Co. (CELG) on Strength (CELG)
Investors sold shares of Celgene Co. (NASDAQ:CELG) on strength during trading on Tuesday. $61.61 million flowed into the stock on the tick-up and $98.02 million flowed out of the stock on the tick-down, for a money net flow of $36.41 million out of the stock. Of all stocks tracked, Celgene had the 0th highest net out-flow for the day. Celgene traded up $2.86 for the day and closed at $130.29
Several research analysts have weighed in on CELG shares. BTIG Research reaffirmed a “buy” rating and set a $138.00 target price on shares of Celgene in a research note on Monday, May 1st. Cantor Fitzgerald set a $159.00 target price on shares of Celgene and gave the stock a “buy” rating in a research note on Thursday, April 27th. Cann reaffirmed a “buy” rating on shares of Celgene in a research note on Thursday, April 27th. Jefferies Group LLC set a $154.00 target price on shares of Celgene and gave the stock a “buy” rating in a research note on Saturday, May 13th. Finally, Vetr lowered shares of Celgene from a “strong-buy” rating to a “buy” rating and set a $132.90 target price for the company. in a research note on Thursday, May 11th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, twenty-two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Celgene presently has an average rating of “Buy” and an average target price of $147.44.
The company has a market cap of $101.07 billion, a P/E ratio of 40.01 and a beta of 1.89. The firm has a 50 day moving average price of $133.54 and a 200-day moving average price of $125.26.
Celgene (NASDAQ:CELG) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.61 by $0.21. The business had revenue of $3.27 billion during the quarter, compared to the consensus estimate of $3.23 billion. Celgene had a return on equity of 52.90% and a net margin of 32.47%. Celgene’s revenue was up 18.7% on a year-over-year basis. During the same quarter last year, the company earned $1.44 EPS. Equities analysts expect that Celgene Co. will post $7.32 EPS for the current year.
In related news, insider Rupert Vessey sold 4,785 shares of the firm’s stock in a transaction that occurred on Thursday, June 15th. The stock was sold at an average price of $120.18, for a total transaction of $575,061.30. Following the completion of the transaction, the insider now owns 4,004 shares in the company, valued at approximately $481,200.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Gilla Kaplan sold 7,500 shares of the firm’s stock in a transaction that occurred on Wednesday, August 2nd. The stock was sold at an average price of $134.52, for a total value of $1,008,900.00. Following the transaction, the director now owns 76,301 shares of the company’s stock, valued at approximately $10,264,010.52. The disclosure for this sale can be found here. Insiders have sold a total of 253,761 shares of company stock valued at $33,792,445 in the last 90 days. 0.95% of the stock is owned by corporate insiders.
Several institutional investors have recently bought and sold shares of the company. Thompson Davis & CO. Inc. increased its position in Celgene by 5.9% in the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 43 shares during the period. Motco increased its position in shares of Celgene by 306.9% in the first quarter. Motco now owns 822 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 620 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. acquired a new position in shares of Celgene during the first quarter valued at about $118,000. Balentine LLC increased its position in shares of Celgene by 83.5% in the second quarter. Balentine LLC now owns 1,057 shares of the biopharmaceutical company’s stock valued at $137,000 after buying an additional 481 shares during the last quarter. Finally, Oakworth Capital Inc. increased its position in shares of Celgene by 60.9% in the first quarter. Oakworth Capital Inc. now owns 1,089 shares of the biopharmaceutical company’s stock valued at $136,000 after buying an additional 412 shares during the last quarter. Institutional investors and hedge funds own 78.34% of the company’s stock.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.